Millar, Jonathan Edward and von Bahr, Viktor and Malfertheiner, Maximillian V. and Ki, Katrina K. and Redd, Meredith A. and Bartnikowski, Nicole and Suen, Jacky Y. and McAuley, Danny Francis and Fraser, John F. (2019) Administration of mesenchymal stem cells during ECMO results in a rapid decline in oxygenator performance. THORAX, 74 (2). pp. 194-196. ISSN 0040-6376, 1468-3296
Full text not available from this repository. (Request a copy)Abstract
Mesenchymal stem cells (MSCs) have attracted attention as a potential therapy for Acute Respiratory Distress Syndrome (ARDS). At the same time, the use of extracorporeal membrane oxygenation (ECMO) has increased among patients with severe ARDS. To date, early clinical trials of MSCs in ARDS have excluded patients supported by ECMO. Here we provide evidence from an ex-vivo model of ECMO to suggest that the intravascular administration of MSCs during ECMO may adversely impact the function of a membrane oxygenator. The addition of clinical grade MSCs resulted in a reduction of flow through the circuit in comparison to controls (0.6 +/- 0.35 L min(-1)vs 4.12 +/- 0.03 L min(-1), at 240 minutes) and an increase in the transoygenator pressure gradient (101 +/- 9 mmHg vs 21 +/- 4 mmHg, at 240 minutes). Subsequent immunohistochemistry analysis demonstrated quantities of MSCs highly adherent to membrane oxygenator fibres. This study highlights the potential harm associated with MSC therapy during ECMO and suggests further areas of research required to advance the translation of cell therapy in this population.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | STROMAL CELLS; ARDS; |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin II |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 17 Apr 2020 11:49 |
| Last Modified: | 17 Apr 2020 11:49 |
| URI: | https://pred.uni-regensburg.de/id/eprint/27576 |
Actions (login required)
 |
View Item |
